News
Latest news from CHV and our portfolio companies
Featured News
Acquisition adds next-generation CLAAS® AcuFORM™ Technology to Gore’s portfolio CAUTION: Investigational Device. Limited by federal (or United States) law to investigational use. Outside the United States, the device is intended exclusively for…
Insights & Impacts: The latest from CHV
EyeCool Therapeutics, Inc. is looking forward to participating in BTIG’s 5th Annual Ophthalmology Day on Monday, December 1,
The Velocity System is a next generation percutaneous AVF technology designed to reduce the need
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems,
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced